Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program

被引：16

作者：

Turner, Philip J. ^{[1
]}

机构：

[1] AstraZeneca, Infect Discovery Dept, Macclesfield SK10 4TG, Cheshire, England

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2006年 / 56卷 / 03期

关键词：

Pseudomonas aeruginosa; susceptibility; meropenem; imipenem;

D O I：

10.1016/j.diagmicrobio.2006.07.015

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

This article examines the activity of meropenem and imipenem against Pseudomonas aeruginosa isolates from the Meropenem Yearly Susceptibility Test Information Collection program between 1997 and 2005. In particular, it examines the activity of meropenem against imipenem-resistant strains and vice versa. Meropenem proved to be active against up to a 3rd of imipenem-resistant strains. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：341 / 344

页数：4

共 50 条

[31] Diversity of β-lactamases produced by imipenem resistant, Pseudomonas aeruginosa isolates from the bloodstream
Peerayeh, Shahin Najar
Mahabadi, Rahim Pirhajati
Toupkanlou, Sanaz Pakbaten
Siadat, Seyed Dauar
BURNS, 2014, 40 (07) : 1360 - 1364
[32] Conjugation of imipenem to silver nanoparticles for enhancement of its antibacterial activity against multidrug-resistant isolates of Pseudomonas aeruginosa
Mahsa Shahbandeh
Anoosh Eghdami
Mehrdad Moosazadeh Moghaddam
Mohammadreza Jalali Nadoushan
Ali Salimi
Mahdi Fasihi-Ramandi
Saber Mohammadi
Mehrnaz Mirzaei
Reza Mirnejad
Journal of Biosciences, 2021, 46
[33] Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results
Turner, Philip J.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 60 (02) : 185 - 192
[34] Conjugation of imipenem to silver nanoparticles for enhancement of its antibacterial activity against multidrug-resistant isolates of Pseudomonas aeruginosa
Shahbandeh, Mahsa
Eghdami, Anoosh
Moosazadeh Moghaddam, Mehrdad
Jalali Nadoushan, Mohammadreza
Salimi, Ali
Fasihi-Ramandi, Mahdi
Mohammadi, Saber
Mirzaei, Mehrnaz
Mirnejad, Reza
JOURNAL OF BIOSCIENCES, 2021, 46 (01)
[35] In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates
Wilhelm, Camila M.
Nunes, Luciana de S.
Martins, Andreza F.
Barth, Afonso L.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 92 (02) : 152 - 154
[36] Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa
GiamarellosBouroulis, EJ
Grecka, P
Giamarellou, H
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (02) : 81 - 86
[37] Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa
Ferretti, Caterina
Poma, Noemi Violeta
Bernardo, Mariano
Rindi, Laura
Cesta, Novella
Tavanti, Arianna
Tascini, Carlo
Di Luca, Mariagrazia
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 37 : 53 - 61
[38] In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa
Shibata, K
Adachi, Y
Kato, E
Nagano, R
Fuse, A
Hashizume, T
Ohtake, N
Okamoto, O
Nakagawa, S
JOURNAL OF ANTIBIOTICS, 1997, 50 (02): : 135 - 138
[39] In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
Young, Katherine
Painter, Ronald E.
Raghoobar, Susan L.
Hairston, Nichelle N.
Racine, Fred
Wisniewski, Douglas
Balibar, Carl J.
Villafania, Artjohn
Zhang, Rumin
Sahm, Daniel F.
Blizzard, Timothy
Murgolo, Nicholas
Hammond, Milton L.
Motyl, Mary R.
BMC MICROBIOLOGY, 2019, 19 (1)
[40] Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem
Bretonniere, Cedric
Jacqueline, Cedric
Caillon, Jocelyne
Guitton, Christophe
Le Mabecque, Virginie
Miegeville, Anne Francoise
Villers, Daniel
Potel, Gilles
Boutoille, David
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (11) : 2423 - 2427

← 1 2 3 4 5 →